CRT and University of Copenhagen announce agreement with ADC Therapeutics to develop antibody treatments for cancer

2016-04-22 00:00:00

CRT and The University of Copenhagen have signed a deal with Switzerland-based ADC Therapeutics SA (ADCT) to license antibodies against a cancer-specific cell surface protein. The antibodies will be used by ADCT to develop a novel Antibody Drug Conjugate (ADC) that could potentially treat a range of cancers.

The antibodies – jointly developed by Cancer Research UK and the University of Copenhagen scientists – target a protein overexpressed on the surface of some cancer cells, which is not expressed on healthy cells.

ADCT intends to incorporate the antibodies into a novel ADC therapeutic using its proprietary linker and pyrrolobenzodiazepine (PBD) cytotoxic warhead technology*. The antibodies are expected to selectively target the PBD cytotoxic to cancer cells, sparing normal tissue.

Thomas Bjørnholm, Pro-Vice-chancellor for Research and Innovation, the University of Copenhagen, said: “We are very pleased and proud that research from the University’s Faculty of Health and Medical Sciences has been licensed to ADCT for the development of new cancer therapeutics. Our mission as a public university is precisely to make sure that our leading-edge research is disseminated and is taken to the market together with commercial partners for the benefit of society at large.”

Dr Keith Blundy, Cancer Research Technology’s chief executive, said: “This important license deal brings together CRT’s access to world class research and ADCT’s cutting edge technology to develop exciting new therapeutics for cancer.

“We hope this agreement will pave the way for promising new ways to treat a range of cancers in a targeted way without damaging healthy tissue.”


For further information, please contact Emily Head, CRT press office, +44 (0)20 3469 6189 or, out of hours, the duty press officer on +44 (0) 7050 264 059.

Notes to editors

* For more information about this technology see:

About Cancer Research Technology
Cancer Research Technology (CRT) is a specialist commercialisation and development company, which aims to develop new discoveries in cancer research for the benefit of cancer patients. CRT works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies. CRT is a wholly owned subsidiary of Cancer Research UK, the world's leading cancer charity dedicated to saving lives through research. Further information about CRT can be found at

About Cancer Research UK

• Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research
• The charity’s pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
• Cancer Research UK receives no government funding for its life-saving research. Every step it makes towards beating cancer relies on every pound donated.
• Cancer Research UK has been at the heart of the progress that has already seen survival rates in the UK double in the last forty years.
• Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
• Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured.

For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1861 or visit Follow us on Twitter and Facebook

About the University of Copenhagen
The University of Copenhagen is the largest university in Denmark and is recognised as one of Europe’s leading universities with a strong core in basic research and research-based education. Six faculties constitute the backbone of the University and the intellectual playground for 5,500 researchers and 40,000 students.

Founded in year 1479, the University of Copenhagen produces knowledge of the highest quality and is among the best universities in Europe. In Nature Index 2015 the University of Copenhagen is on the Top 50 list of institutions publishing articles in Nature and Science journals.

The University has an annual income of EUR 1.1 billion and has produced eight Nobel Prize award winners. Situated in the centre of the “Copenhagen Science City”, the University of Copenhagen is currently undertaking a number of very large infrastructure projects, such as the Niels Bohr Building and the Maersk Building. The investments amount to more than EUR 700 million and will provide state-of-the-art research facilities for leading-edge research centres.

For further information about the University of Copenhagen visit Information about collaboration with researchers and/or licensing opportunities is available upon contacting the Technology Transfer Office at